pmed.1003668.s004.pdf (199.3 kB)
Ethics approval document.
journal contribution
posted on 2021-06-24, 17:27 authored by Piero Ruggenenti, Paolo Cravedi, Eliana Gotti, Annarita Plati, Maddalena Marasà, Silvio Sandrini, Nicola Bossini, Franco Citterio, Enrico Minetti, Domenico Montanaro, Ettore Sabadini, Regina Tardanico, Davide Martinetti, Flavio Gaspari, Alessandro Villa, Annalisa Perna, Francesco Peraro, Giuseppe Remuzzi(PDF)
History
Usage metrics
Categories
Keywords
87 biopsied patientsJuly 2012CsA doseGFRmicroemulsion maintenance immunosup...filtration ratelow-dose thymoglobulingraft survivalPrimary endpointsubclinical rejectionsdonor kidney transplantbiopsy-proven subclinicalinterquartile rangetransplant centersACRstudy limitationslow-dose CsAunblinded designgraft functionEUDRACT 2006-005604-14HRAugust 2016. Between-group donorAEkidney transplant recipientsfollow-up CsA blood levelsChronicity scoresMMFJune 20071- weeksample sizeMycophenolate mofetilallograft nephropathymulticenter trialDGF21 patientsCIrandomized trial Backgrounddonor kidney transplant recipientsIQRhazard ratiobiopsy-proven CANAZAlow-dose cyclosporine immunosuppressionfindings ATHENAmycophenolate mofetilgraft outcomeTrial registration ClinicalTrials.g...low-dose cyclosporine
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC